Hims & Hers Health (NYSE:HIMS) Trading Down 1.1% on Insider Selling

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) traded down 1.1% on Wednesday following insider selling activity. The company traded as low as $44.64 and last traded at $44.87. 7,539,135 shares were traded during mid-day trading, a decline of 77% from the average session volume of 33,440,219 shares. The stock had previously closed at $45.35.

Specifically, insider Soleil Boughton sold 2,571 shares of the stock in a transaction on Monday, August 25th. The stock was sold at an average price of $44.53, for a total transaction of $114,486.63. Following the completion of the transaction, the insider directly owned 150,450 shares in the company, valued at approximately $6,699,538.50. This represents a 1.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Andrew Dudum sold 128,127 shares of the firm’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $45.06, for a total value of $5,773,402.62. Following the transaction, the chief executive officer owned 89,521 shares of the company’s stock, valued at $4,033,816.26. This trade represents a 58.87% decrease in their ownership of the stock. The disclosure for this sale can be found here.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on HIMS. Zacks Research cut Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Morgan Stanley restated an “equal weight” rating and set a $40.00 target price on shares of Hims & Hers Health in a report on Wednesday, June 11th. Piper Sandler restated a “neutral” rating and set a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. UBS Group set a $30.00 target price on Hims & Hers Health in a report on Monday, June 23rd. Finally, Needham & Company LLC restated a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Two investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Hims & Hers Health presently has a consensus rating of “Reduce” and a consensus price target of $38.92.

Hims & Hers Health Stock Down 2.8%

The firm has a 50 day moving average price of $50.76 and a 200-day moving average price of $45.84. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. The firm has a market cap of $9.96 billion, a PE ratio of 55.09, a PEG ratio of 3.06 and a beta of 2.08.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $544.83 million during the quarter, compared to analysts’ expectations of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business’s quarterly revenue was up 72.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Signaturefd LLC boosted its stake in shares of Hims & Hers Health by 17.7% in the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock valued at $76,000 after buying an additional 388 shares during the period. GAMMA Investing LLC lifted its stake in Hims & Hers Health by 128.5% during the first quarter. GAMMA Investing LLC now owns 5,143 shares of the company’s stock worth $152,000 after purchasing an additional 2,892 shares during the last quarter. New York State Teachers Retirement System lifted its stake in Hims & Hers Health by 95.2% during the first quarter. New York State Teachers Retirement System now owns 194,795 shares of the company’s stock worth $5,756,000 after purchasing an additional 94,983 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in Hims & Hers Health during the fourth quarter worth approximately $1,230,000. Finally, Fifth Third Bancorp lifted its stake in Hims & Hers Health by 165.4% during the first quarter. Fifth Third Bancorp now owns 1,542 shares of the company’s stock worth $46,000 after purchasing an additional 961 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.